AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.195
-0.005 (-2.50%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.200
Open0.200
Bid0.185 x 0
Ask0.200 x 0
Day's Range0.190 - 0.200
52 Week Range0.135 - 0.450
Volume31,200
Avg. Volume83,965
Market Cap14.15M
Beta-0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.052
Earnings DateApr 30, 2018 - May 4, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire3 days ago

    Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”) is pleased to announce a recent expansion of the market opportunity for its reformulated anti-nausea transdermal patch, AQS1303, into the European market. Diclectin®, the oral reference product for AQS1303 for the treatment of nausea and vomiting of pregnancy, has recently received marketing authorization in the United Kingdom under the brand name Xonvea®. Aequus plans to launch AQS1303 in countries where an original oral form has been approved and an accelerated path to approval may exist for reformulated products.

  • GlobeNewswire6 days ago

    Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), is pleased to announce that it has agreed to new terms for its promotional service agreement with Sandoz on PRVistitan™ (“Vistitan”) with improved economics and a term extension of an additional year. Aequus began promotional efforts in May 2016 for Vistitan (bimatoprost 0.03%, ophthalmic solution), which is approved in Canada for the reduction of elevated intraocular pressure (“IOP”) in patients with open angle glaucoma or ocular hypertension. Under the previous agreement, Aequus and Sandoz split revenues based upon an agreed to tiered structure over the term.

  • GlobeNewswire9 days ago

    Aequus Announces New Independent Director to its Board

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that following the completion of its Annual General Meeting held on July 10, 2018, Mr. Damien King has joined its Board of Directors to fill the seat previously held by Dr. Fotios Plakogiannis who did not stand for re-election. Mr. King is currently the Director of Sales with Merz Pharma Canada (“Merz”) and sits as a founding member of their Senior Leadership Team.

  • GlobeNewswirelast month

    Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch

    Aequus and Corium have expanded their relationship to include Aequus’ long-acting, transdermal patch for nausea and vomiting in pregnancy, AQS1303; Corium will utilize Corplex™, its industry leading, proprietary ...

  • GlobeNewswirelast month

    Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto® Capsulotomy System (“Zepto”), a precision pulse capsulotomy device, have been successfully completed this week by Dr. Ike Ahmed at the Kensington Eye Institute in Toronto, Ontario. Dr. Ike Ahmed is world-renowned for his skills in the diagnosis and surgical treatment of highly complex eye diseases.

  • GlobeNewswire2 months ago

    Aequus Provides First Quarter 2018 Financial and Corporate Highlights

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the first quarter ended March 31, 2018 and associated Company developments.

  • GlobeNewswire2 months ago

    Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), is pleased to announce it will be formally launching the Zepto® Precision Pulse Capsulotomy System (“Zepto”) in Canada on June 1, 2018 during the Canadian Ophthalmological Society’s 2018 Annual Meeting and Exhibition. Aequus recently announced being appointed as the exclusive Canadian distributor for this product, under a commercial agreement with Mynosys Cellular Devices, an ophthalmology focused medical device company based in Fremont, California (“Mynosys”). Zepto is a novel medical device used during cataract surgery to produce a consistent, high quality, round capsulotomy in milliseconds.

  • GlobeNewswire3 months ago

    Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch

    FDA has confirmed that an abbreviated 505 regulatory pathway would be appropriate for the submission of AQS1303, Aequus’ long-acting anti-nausea patch for nausea and vomiting associated with pregnancy, ...

  • GlobeNewswire3 months ago

    Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the full year ended December 31, 2017. “With a now established track record of launching products, a sales and marketing team providing full Canadian coverage, and a history of deals with major players, Aequus now finds itself in a strong position as a preferred partner providing a unique and flexible deal structure in the Canadian marketplace,” said Doug Janzen, Chairman and CEO of Aequus.

  • GlobeNewswire3 months ago

    Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018

    VANCOUVER, British Columbia, April 26, 2018-- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced ...

  • Baystreet3 months ago

    Big Pharma says It Must Collaborate with Juniors to Revive Real Innovation

    Innovation in the pharmaceutical industry has come a long way in the last few decades, but with the ...

  • Baystreet4 months ago

    Drug Makers Use Nanotechnology to Improve Delivery and Dosing

    In order to advance the delivery of specialized medicines and dosage, scientists are looking to improvements ...

  • PR Newswire5 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.

  • CNW Group5 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (TSX-V:AQS.V - News) (OTCQB:AQSZF - News) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB:EHVVF - News) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.

  • PR Newswire5 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.

  • Baystreet5 months ago

    New Drug Delivery Technologies Extending to Even Aspirin

    Missed drug dosses are not only risky to concerned patients, but to the global healthcare system as ...

  • Marketwired6 months ago

    Aequus Announces Closing of $300,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...

  • Marketwired6 months ago

    Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch

    Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced plans to advance its...

  • Marketwired6 months ago

    Aequus Announces Change to Proposed $300,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...

  • Marketwired6 months ago

    Aequus Announces Proposed $300,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...